Choshi Haruki, Watanabe Mototsugu, Furukawa Shinichi, Ujike Hiroyuki, Kataoka Kazuhiko
Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center.
Acta Med Okayama. 2022 Oct;76(5):585-591. doi: 10.18926/AMO/64040.
Pulmonary metastatic resection is a standard therapy for renal cell carcinoma (RCC). Although patients with pulmonary metastases who do not undergo any treatment have poor prognoses, it has been reported that resection for pulmonary metastases yields good clinical outcomes. We investigated the prognoses of the 10 Japanese patients (eight males, two females) who underwent a surgical resection of pulmonary metastasectomy from RCC at our institution between April 1, 2012 and March 31, 2020 and analyzed the prognostic factors. We determined the prognoses and calculated the 5-year overall survival (OS) and disease-free survival (DFS) rates. To identify prognostic factors, we compared the median DFS duration for each factor. Elderly patients (median age, 75.5 years) were more predominant compared to previous studies, and all 10 patients underwent a complete resection. The 5-year DFS rate was 30.5% (95%CI: 0.045-0.63) and the 5-year OS rate was 80% (95%CI: 0.20-0.97). The following factors were associated with better prognosis: female, disease-free interval≥36 months, and metastases size<12 mm. These results indicate that complete resection for pulmonary metastases from RCC resulted in good clinical outcomes, particularly for patients with better prognostic factors.
肺转移瘤切除术是肾细胞癌（RCC）的标准治疗方法。尽管未接受任何治疗的肺转移患者预后较差，但据报道，肺转移瘤切除术可产生良好的临床结果。我们调查了2012年4月1日至2020年3月31日期间在我院接受RCC肺转移瘤手术切除的10例日本患者（8例男性，2例女性）的预后，并分析了预后因素。我们确定了预后并计算了5年总生存率（OS）和无病生存率（DFS）。为了确定预后因素，我们比较了每个因素的中位DFS持续时间。与先前的研究相比，老年患者（中位年龄75.5岁）更为多见，所有10例患者均接受了根治性切除。5年DFS率为30.5%（95%CI：0.045-0.63），5年OS率为80%（95%CI：0.20-0.97）。以下因素与较好的预后相关：女性、无病间期≥36个月和转移瘤大小<12mm。这些结果表明，RCC肺转移瘤的根治性切除可产生良好的临床结果，特别是对于具有较好预后因素的患者。
